Search for Clinical Trial Results

Sponsored By

Mucopolysaccharidosis II - 29 Studies Found

Status Study
Recruiting Study Name: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
Condition: Hunter Syndrome
Date: 2014-01-19
Completed Study Name: A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723
Condition: Mucopolysaccharidosis II
Date: 2012-05-17
Interventions:
  • Drug: Idursulfase recombinant

Completed Study Name: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Condition:
  • Hunter Syndrome
  • Mucopolysaccharidosis II<
    Date: 2008-02-28
    Interventions: Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly
Completed Study Name: Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Condition: Hunter Syndrome
Date: 2011-10-06
Interventions: Other: No treatment
Completed Study Name: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy
Condition:
  • Hunter Syndrome
  • Mucopolysaccharidosis II<
    Date: 2008-01-22
    Interventions: Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg weekly
Completed Study Name: An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
Condition: Hunter Syndrome
Date: 2009-04-16
Interventions: Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally
Completed Study Name: A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Condition: Hunter Syndrome
Date: 2009-06-12
Interventions:
  • Other: Control 3 dose cohorts

Enrolling by invitation Study Name: Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094
Condition: Hunter Syndrome
Date: 2015-04-01
Interventions: Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m
Completed Study Name: Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Condition: Hunter Syndrome
Date: 2009-07-09
Interventions:
  • Behavioral: Neurobehavioral testing

Active, not recruiting Study Name: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
Condition: Hunter Syndrome
Date: 2014-01-17
Interventions:
  • Biological: idursulfase-IT 10m
Next >>>